Abstract
The COVID-19 pandemic that swept the world at the beginning of 2020 is still raging. It is well established that in addition to respiratory symptoms, COVID-19 can also have neurological manifestations that may result from direct or indirect neurological damage. But are these neurological manifestations coincidental or causal? From a neurological perspective, these symptoms could be the result of neurological damage following SARS-CoV-2 infection, or they could be coincidental, from causes such as secondary systemic complications or side effects of drug treatment. The aim of this review is to raise clinician’s awareness to the development of neurological impairment in SARS-CoV-2 infected patients in the current normative prevention and control.
Highlights
In the past ten months, COVID-19, formerly known as 2019 novel coronavirus, has become a serious threat to global health
The coronavirus strain responsible for causing COVID-19 belongs to the genus Betacoronavirus and can be transmitted from person to person [2]
Neurological manifestations of COVID-19 stroke and disorders of smell and taste, etc. These symptoms could be the result of neurological damage following SARS-CoV-2 infection, or they could be coincidental, resulting from causes such as secondary systemic complications or side effects of drug treatment
Summary
In the past ten months, COVID-19, formerly known as 2019 novel coronavirus, has become a serious threat to global health. These symptoms could be the result of neurological damage following SARS-CoV-2 infection, or they could be coincidental, resulting from causes such as secondary systemic complications or side effects of drug treatment. Based on the existing COVID-19 literature, this paper further discusses the mechanism of neurological damage after SARS-CoV-2 infection in relation to the neurological manifestations that occur in infected patients (Figure 1). Of the reported COVID-19 patients with cerebrovascular disease, the majority had ischemic strokes [7,9,10,11,12,13,14,15] and a small proportion had hemorrhagic strokes [7, 9, 14]. The high prevalence of cerebrovascular disease among COVID-19 patients does not in itself prove that incidence of cerebrovascular disease in COVID-19 patients is a causal
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
